Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902219-25-000015
Filing Date
2025-02-06
Accepted
2025-02-06 09:38:17
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10558
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 4387
  Complete submission text file 0000902219-25-000015.txt   16999
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 0000

Mailing Address HULSTERWEG 82 PL VENLO P7 5912
Business Address HULSTERWEG 82 PL VENLO P7 5912 31-77-35566-00
QIAGEN N.V. (Subject) CIK: 0001015820 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-54659 | Film No.: 25595758
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)